Date:11/12/2012

ns, including without limitation, the Company's ability to successfully integrate acquired businesses, the risks that the acquired businesses may not operate as effectively and efficiently as expected even if otherwise successfully integrated, the risks that acquisitions may involve unexpected costs or unexpected liabilities, including the risks and challenges associated with the Company's recent acquisition of Gen-Probe and operations in China; manufacturing risks, including the Company's reliance on a single or limited source of supply for key components, and the need to comply with especially high standards for the manufacture of many of its products; the Company's ability to predict accurately the demand for its products, and products under development, and to develop strategies to address its markets successfully; the early stage of market development for certain of the Company's products; the Company's leverage risks, including the Company's obligation to meet payment obligations and financial covenants associated with its debt; risks related to the use and protection of intellectual property; expenses, uncertainties and potential liabilities relating to litigation, including, without limitation, commercial, intellectual property, employment and product liability litigation; technical innovations that could render products marketed or under development by the Company obsolete; competition; the risks of conducting business internationally, including the effect of exchange rate fluctuations on those operations; and the Company's ability to attract and retain qualified personnel.

The risks included above are not exhaustive. Other factors that could adversely affect the combined company's business and prospects are described in the filings made by the Company with the SEC. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or
'/>"/>

SOURCE Hologic, Inc. Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
Related medicine technology :

1. Hologic to Showcase Advancement Simplifying Removal of Large Intrauterine Pathology at AAGL
2. Hologic, Inc. Marks Breast Cancer Awareness Month by Ringing the Opening Bell at NASDAQ and Taking 3D Mammography on the Road
3. Hologic Announces Verdict In Patent Infringement Suit
4. Hologic To Participate In The Morgan Stanley Global Healthcare Conference
5. Senator Blumenthal, a Strong Advocate for Womens Health, Visits Hologics Manufacturing Facility in Danbury, CT
6. Hologic Completes Acquisition Of Gen-Probe
7. Hologic Announces Third Quarter Fiscal 2012 Operating Results
8. Hologic Announces Pricing Of Financing In Connection With Acquisition Of Gen-Probe
9. Hologic Human Papillomavirus (HPV) High-Risk Test Approved for Use in The Netherlands Population Cervical Screening Programme
10. Hologic and Gen-Probe Announce Clearance from German Federal Cartel Office for Hologics Acquisition of Gen-Probe
11. Hologic And Gen-Probe Provide Update On Pending Transaction